FDA suspends Valneva’s license of chikungunya vaccine IXCHIQ in US

The sudden subsequent decision to suspend IXCHIQ is based on updated VAERS data

Lilly's Verzenio scores first OS improvement in breast Cancer

Treatment with Verzenio also resulted in sustained invasive disease-free survival and distant relapse-free survival benefit

SMS Pharmaceuticals receives EIR from USFDA for Central Laboratory Analytical Services

The inspection, conducted from June 23 to June 25, 2025, concluded with zero Form 483 observations

India releases first-ever National Guidelines/SOPs for animal blood transfusion and blood banks

Guidelines aim to establish state-regulated veterinary blood banks

FDA approves first immunotherapy for recurrent respiratory papillomatosis

Pfizer’s sickle cell disease candidate fails Phase III trial

Inclacumab was generally well tolerated in THRIVE-131

European Commission grants approval of Ogsiveo

OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors

UFlex posts Q1 FY26 PAT at Rs. 58 Cr

The company’s virgin PET chips plant in Egypt, commissioned in Q4 FY25, achieved 74.8 per cent capacity utilization in its first full quarter. In India, the Panipat facility operated at 96.6 per cent utilization

Anthem Biosciences posts Q1 FY26 PAT at Rs. 135.8 Cr

The CRDMO segment contributed Rs. 452.7 crore, recording a robust 70.5 per cent YoY increase

Apollo Hospitals Q1 FY26 PAT up 42% to Rs. 433 Cr

Apollo has also announced plans to add over 4,300 beds in the next five years with an investment of over Rs. 7,600 crore